Advancing diagnostics and therapy to reach universal cure in childhood ALL
R Pieters, CG Mullighan, SP Hunger - Journal of Clinical Oncology, 2023 - ascopubs.org
Systemic combination chemotherapy and intrathecal chemotherapy markedly increased the
survival rate of children with ALL. In the past two decades, the use of minimal (measurable) …
survival rate of children with ALL. In the past two decades, the use of minimal (measurable) …
How I use risk factors for success or failure of CD19 CAR T cells to guide management of children and AYA with B-cell ALL
RM Myers, NN Shah, MA Pulsipher - Blood, 2023 - ashpublications.org
By overcoming chemotherapeutic resistance, chimeric antigen receptor (CAR) T cells
facilitate deep, complete remissions and offer the potential for long-term cure in a substantial …
facilitate deep, complete remissions and offer the potential for long-term cure in a substantial …
Head and neck cancer immunotherapy: molecular biological aspects of preclinical and clinical research
Simple Summary Immune therapies are the most recent advancements in the field of cancer
and particularly in head and neck cancer. Cancer spread is attributed to the failure of …
and particularly in head and neck cancer. Cancer spread is attributed to the failure of …
INSPIRED Symposium Part 2: Prevention and Management of Relapse Following CAR T-cell therapy for B-ALL
AJ Lamble, A Moskop, MA Pulsipher, SL Maude… - … and Cellular Therapy, 2023 - Elsevier
While CD19-directed chimeric antigen receptor (CAR) T cell therapy for relapsed/refractory
B-cell acute lymphoblastic leukemia (B-ALL) has been transformative in in inducing and …
B-cell acute lymphoblastic leukemia (B-ALL) has been transformative in in inducing and …
Chimeric antigen receptor (CAR) T-cell products for pediatric cancers: why alternative development paths are needed
C Rossig, AD Pearson, G Vassal, N Scobie… - Journal of Clinical …, 2024 - ascopubs.org
Effective multimodal therapies for pediatric cancers today achieve long-term survival in
about 80% of patients. 1 Prospective randomized, multicenter trials performed by academic …
about 80% of patients. 1 Prospective randomized, multicenter trials performed by academic …
[HTML][HTML] Allogeneic chimeric antigen receptor T cells for children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
F Locatelli, F Del Bufalo, C Quintarelli - Haematologica, 2024 - ncbi.nlm.nih.gov
Chimeric antigen receptor (CAR) T-cell therapy has emerged as a breakthrough cancer
therapy over the past decade. Remarkable outcomes in B-cell lymphoproliferative disorders …
therapy over the past decade. Remarkable outcomes in B-cell lymphoproliferative disorders …
[HTML][HTML] Chimeric antigen receptor T-cell therapy in childhood acute myeloid leukemia: how far are we from a clinical application?
S Naik, MP Velasquez, S Gottschalk - Haematologica, 2024 - ncbi.nlm.nih.gov
Recurrent and/or refractory (R/R) pediatric acute myeloid leukemia (AML) remains a
recalcitrant disease with poor outcomes. Cell therapy with genetically modified immune …
recalcitrant disease with poor outcomes. Cell therapy with genetically modified immune …
[HTML][HTML] INSPIRED Symposium Part 4A: access to CAR T cell therapy in unique populations with B cell acute lymphoblastic leukemia
LE Winestone, D Bhojwani, S Ghorashian… - … and Cellular Therapy, 2023 - Elsevier
The approval of tisagenlecleucel (tisa-cel) for use in children with B cell acute lymphoblastic
leukemia (B-ALL) was based on the phase 2 ELIANA trial, a global registration study …
leukemia (B-ALL) was based on the phase 2 ELIANA trial, a global registration study …
Preventing relapse after CD19 CAR T-cell therapy for pediatric ALL: the role of transplant and enhanced CAR T cells
AC Talleur, S Naik, S Gottschalk - Hematology, 2023 - ashpublications.org
CD19-specific chimeric antigen receptor (CAR) T-cell therapy has become an integral part of
our treatment armamentarium for pediatric patients with relapsed or refractory B-cell acute …
our treatment armamentarium for pediatric patients with relapsed or refractory B-cell acute …
INSPIRED Symposium Part 4B: Chimeric Antigen Receptor T Cell Correlative Studies—Established Findings and Future Priorities
Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of B cell
malignancies, with multiple CAR T cell products approved for numerous indications by …
malignancies, with multiple CAR T cell products approved for numerous indications by …